A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Exclusion Criteria

• •1. History of allergies to any components of IBI3002 or placebo.
• •2. History of blood or needle sickness, or those who cannot tolerate venipuncture.
• •3. Female participants who are pregnant or breastfeeding at screening or randomization.
• •4. History of participating in a clinical trial within 1 month or 5 half-lives of the test drug (whichever is longer) prior to randomization, or those who are currently participating in a clinical trial.
• •5. History of severe infection or significant injury within 6 months, or surgery within 3 months, or any infection requiring systemic medication within 1 month prior to screening or randomization.
• •6. History of live or attenuated vaccination within 1 month prior to randomization, or those who plan to be vaccinated during the study.
• •7. For asthmatics only: history of a life-threatening asthma attack that required mechanical ventilation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years prior to randomization.
• •8. For asthmatics only: history of asthma worsen or exacerbation resulting in emergency room (ER) visits or overnight hospitalizations, or an increase in asthma maintenance therapy, or use of systemic glucocorticoids within the last 3 months prior to randomization.